In a noteworthy recognition of corporate excellence, two leading pharmaceutical giants from Bangladesh, Square Pharmaceuticals and Beximco Pharmaceuticals, have secured positions on Forbes Magazine’s esteemed “Asia’s 200 Best Under a Billion” list for the year 2023.
Forbes Magazine, renowned for its global business rankings, annually curates this exclusive list, spotlighting the top 200 publicly listed companies in the Asia-Pacific region with sales under $1 billion. The selection process involves a meticulous evaluation of corporate performance from a vast pool of over 20,000 small and mid-sized businesses across the Asia-Pacific region.
Square Pharmaceuticals emerges as a standout performer, boasting a remarkable sales figure of $646 million, accompanied by a net income of $210 million. The company’s market value, a significant indicator of its influence, stands impressively at $2.04 billion. Square Pharmaceuticals’ inclusion in Forbes’ prestigious list underscores its resilience and prowess in navigating the competitive pharmaceutical landscape.
Beximco Pharmaceuticals, another stalwart in the industry, secures its position with reported sales of $319 million. The company’s net income stands at $47 million, reflecting its financial strength and stability. With a market value of $600 million, Beximco Pharmaceuticals reinforces its status as a key player in the pharmaceutical sector.
Forbes Magazine’s recognition serves as a testament to the unwavering commitment, strategic vision, and operational excellence demonstrated by both Square Pharmaceuticals and Beximco Pharmaceuticals. These accolades not only elevate the prestige of the companies but also bring international acclaim to Bangladesh’s pharmaceutical industry.
As these pharmaceutical giants continue to make significant strides in the Asia-Pacific region, their success becomes emblematic of the broader economic prowess and growth potential of Bangladesh on the global stage. The acknowledgment by Forbes further solidifies their standing as beacons of success in the dynamic and competitive pharmaceutical landscape.
For more updates, follow Markedium.
